BiPar Sciences

BiPar Sciences is a technology company.

Active

Updated: Mar 22, 2026 ·

About

BiPar Sciences develops novel tumor-selective drugs, primarily focusing on PARP inhibitors, to address urgent unmet needs in cancer therapy. The company's lead experimental product, BSI-201, targets various cancer types, including those that have become resistant to existing treatments. This therapeutic approach aims to specifically interrupt DNA repair pathways in cancer cells, thereby enhancing the efficacy of chemotherapy and radiation while minimizing harm to healthy tissue.

The company was founded in 2002 by a team including Tom White, G. Kirk Raab, John Schembri, and Allan Basbaum. Their collective insight stemmed from the potential of exploiting vulnerabilities in cancer cell biology, particularly in DNA repair mechanisms, to create more effective and targeted interventions. With its base in South San Francisco, California, BiPar Sciences aimed to translate advanced scientific understanding into tangible clinical solutions.

BiPar Sciences' products are intended for cancer patients, especially those grappling with difficult-to-treat or therapy-resistant forms of the disease. The company’s vision centered on pioneering new therapeutic classes that could significantly improve patient outcomes by offering highly specific and potent anti-cancer activity. It sought to advance the frontier of oncology by developing therapies that selectively target tumor cells, ultimately striving to provide more durable and impactful treatments.

Recent News & Mentions

Jan 1, 2009FundingBiPar Sciences - Series C Feb 1, 2007FundingBiPar Sciences - Series B Dec 1, 2004FundingBiPar Sciences - Series A

Financial History

BiPar Sciences has raised $68.0M across 3 funding rounds. Most recently, it raised $20.0M Series C in January 2009.

Total Raised

$68.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Jan 1, 2009	$20.0M Series C	Canaan Partners, Domain Associates, Santé Ventures
Feb 1, 2007	$35.0M Series B	Canaan Partners, Domain Associates, Santé Ventures
Dec 1, 2004	$13.0M Series A	Canaan Partners

Financial History

BiPar Sciences has raised $68.0M across 3 funding rounds.

Total Raised

$68.0M

Valuation

N/A

Deep Dive

BiPar Sciences is a clinical‑stage biopharmaceutical company developing tumor‑selective PARP inhibitor therapies for oncology indications, focused on advancing a pipeline—led historically by compounds such as BSI‑201—targeting cancers with elevated PARP1 expression to improve efficacy and safety versus nonselective approaches[1][2].

High‑Level Overview

Mission: Develop and commercialize tumor‑selective PARP (poly‑ADP‑ribose polymerase) inhibitor drugs to treat cancers that overexpress PARP1, aiming to increase therapeutic index and patient benefit in selected tumor types[1][3].- Investment philosophy / Key sectors / Impact on startup ecosystem: As a portfolio subject (clinical biopharma), BiPar operates in the oncology drug‑development sector (small molecule therapeutics / targeted oncology). Its primary ecosystem impact is advancing precision oncology approaches and biomarker‑driven patient selection that can guide later‑stage academic and commercial programs rather than acting as an investor itself[2][3].- Product, customers, problem solved, growth momentum: BiPar develops PARP inhibitor drug candidates (e.g., BSI‑201) intended for patients with cancers that overexpress PARP1; the product addresses the need for more selective DNA‑repair targeted therapies with improved tumor selectivity and potential for better efficacy/safety in selected tumor populations[2][3]. As a clinical‑stage company, growth momentum is measured by biomarker data, clinical trial progress and executive hires (for example, recent appointment of a CFO), indicating active development and corporate scaling[1][2].

Origin Story

Founding year & evolution: Publicly available summaries identify BiPar Sciences as a U.S.‑based, clinical‑stage biopharmaceutical company focused on PARP inhibitors; archival coverage and its pipeline presentations date its active development through the 2000s and into later clinical stages, with ongoing efforts to refine biomarker‑guided programs[2][3].- Founders / founders’ background / idea emergence: Public sources emphasize the company’s scientific leadership (senior executives and physicians cited in presentations) and research that identified PARP1 overexpression across specific tumor types using genomic databases—this biomarker insight shaped the company’s strategy to target indications with higher probability of clinical success[3].- Early traction / pivotal moments: Key early validation included molecular biomarker data showing PARP1 overexpression in ovarian, breast (intraductal), lung and uterine cancers, presented at a major conference (AACR‑NCI‑EORTC), which informed clinical development plans for BSI‑201 and similar candidates[3]. More recent corporate milestones include senior executive appointments (for example, a named CFO)[1].

Core Differentiators

Biomarker‑driven focus: Uses genomic biomarker data (PARP1 expression) to prioritize tumor types most likely to respond, enabling targeted clinical development and patient selection[3].- Tumor‑selective PARP inhibition: Positioning on *tumor selectivity*—aiming to differentiate from earlier, less selective PARP inhibitors by improving therapeutic index and reducing off‑tumor effects[2][3].- Clinical‑stage validation: Advancement of candidates into clinical trials and presentations at major scientific meetings provide translational credibility and early clinical data to support the approach[2][3].- Experienced clinical leadership and corporate scaling: Ongoing executive hires and corporate structuring consistent with a company transitioning through clinical development[1].

Role in the Broader Tech/Healthcare Landscape

Trend alignment: BiPar rides the precision oncology and DNA‑damage response (DDR) therapy trend, where PARP inhibitors have become an established class for certain cancers (e.g., BRCA‑mutated tumors); BiPar’s emphasis on PARP1 overexpression expands patient stratification beyond mutation status[3].- Timing and market forces: Growing acceptance of biomarker‑guided therapies, regulatory pathways for targeted oncology drugs, and demand for therapies with better safety/efficacy profiles favor companies that can demonstrate clear predictive biomarkers and clinical benefit[2][3].- Influence: By demonstrating PARP1 overexpression across tumor types and pursuing tumor‑selective inhibitors, BiPar contributes to broader efforts to refine which patients benefit from DDR inhibitors and to the scientific dialogue on biomarker selection in oncology[3].

Quick Take & Future Outlook

What’s next: Continued clinical development of lead PARP inhibitor candidates, further biomarker validation, and progression through clinical trial milestones and regulatory interactions are the immediate next steps; corporate hires signal preparation for later‑stage development activities[1][2].- Trends that will shape the journey: Evolving standards for patient selection (multi‑omic biomarkers), combination strategies with immunotherapy or other targeted agents, and competition from established PARP inhibitor developers will affect BiPar’s prospects. Success will depend on demonstrating superior tumor selectivity, meaningful clinical benefit in biomarker‑selected populations, and a clear safety advantage[2][3].- How influence might evolve: If BiPar’s tumor‑selective approach yields clear clinical differentiation, the company could influence how PARP inhibitors are deployed (biomarker stratification beyond BRCA status) and potentially become an acquisition target for larger oncology players seeking differentiated DDR assets.

Quick take: BiPar Sciences is a clinical‑stage oncology biotech centered on tumor‑selective PARP inhibition and biomarker‑driven development; its near‑term value hinges on clinical readouts and further validation that PARP1 overexpression can reliably predict therapeutic benefit, which would strengthen its position in the precision oncology landscape[2][3][1].

Sources used: company and industry coverage noting BiPar’s clinical‑stage PARP inhibitor programs and biomarker data, plus a recent corporate executive appointment announcement[1][2][3].

Sources

Frequently Asked Questions

How much funding has BiPar Sciences raised?

BiPar Sciences has raised $68.0M in total across 3 funding rounds.

Who are BiPar Sciences's investors?

BiPar Sciences's investors include Canaan Partners, Domain Associates, Santé Ventures.